10-Q: SI-BONE Q3 Revenue Jumps 20.6%, Narrows Loss

SI-BONE, Inc. reported a 20.6% increase in Q3 2025 revenue to $48.7 million and significantly reduced its net loss, driven by expanded product offerings and increased case volumes.

Summary

• Revenue for Q3 2025 increased by 20.6% to $48.7 million, and for the nine months ended September 30, 2025, increased by 22.3% to $144.6 million, primarily due to higher U.S. case volumes and an expanded product portfolio.
• Net loss for Q3 2025 improved to $4.6 million from $6.6 million in Q3 2024, and for the nine months ended September 30, 2025, improved to $17.3 million from $26.4 million in the prior year period.
• Gross margin slightly increased to 79.8% for both the three and nine months ended September 30, 2025, compared to 79.1% and 79.0% respectively in the prior year, driven by lower product costs and favorable product mix.
• Operating cash flow significantly improved, with net cash used in operating activities decreasing to $2.4 million for the nine months ended September 30, 2025, from $13.6 million in the same period last year.
• The company entered into a Fourth Amendment to its Loan and Security Agreement with First-Citizens Bank & Trust Company on September 25, 2025, revising financial covenants related to Net Revenue and Adjusted EBITDA.
• Daniel Wolf resigned from the Board of Directors effective November 6, 2025, and entered into a consulting agreement with the company, with accelerated vesting of 8,675 restricted stock units.

Sentiment

Score: 7

Explanation: The company shows strong revenue growth and a significant reduction in net losses, indicating positive operational momentum. However, it continues to incur losses, has an increasing accumulated deficit, and faces notable risks including a DOJ investigation, supply chain vulnerabilities, and reimbursement uncertainty, which temper the overall positive sentiment.

Positives

• Strong revenue growth: 20.6% increase in Q3 2025 revenue to $48.7 million and 22.3% increase for the nine months to $144.6 million.
• Improved profitability: Net loss narrowed to $4.6 million in Q3 2025 from $6.6 million in Q3 2024, and to $17.3 million for the nine months from $26.4 million in the prior year.
• Increased gross margin: Rose to 79.8% in Q3 2025 from 79.1% in Q3 2024, and to 79.8% for the nine months from 79.0% in the prior year, attributed to lower product costs and favorable product mix.
• Significant improvement in operating cash flow: Net cash used in operating activities decreased by $11.2 million to $2.4 million for the nine months ended September 30, 2025.
• Expanded product portfolio and increased U.S. case volumes are driving revenue growth.
• Successful clinical trial results: SAFFRON study showed higher mobility recovery with iFuse TORQ for sacral fragility fractures (published May 2025), and STACI study showed low adverse event rate and early improvement in pain/function with iFuse TORQ by interventional physicians (published June 2025). SILVIA study met its primary clinical endpoint, reducing new-onset SI joint pain.
• Increased sales force productivity: Trailing twelve-month average revenue per territory sales manager increased to approximately $2.1 million as of September 30, 2025, from $1.8 million a year prior.
• Maintained compliance with all debt covenants as of September 30, 2025.

Negatives

• Continued net losses: The company reported a net loss of $4.6 million in Q3 2025 and $17.3 million for the nine months ended September 30, 2025, and expects to incur additional losses.
• Increased accumulated deficit: Rose to $448.6 million as of September 30, 2025, from $431.4 million at December 31, 2024.
• Decrease in cash and cash equivalents: Cash and cash equivalents decreased by $8.461 million for the nine months ended September 30, 2025.
• Shift to net cash used in investing activities: From $8.3 million provided in 9 months 2024 to $8.9 million used in 9 months 2025, primarily due to purchases of marketable securities exceeding maturities.
• Increased inventory build-up: Inventory increased from $27.1 million at December 31, 2024, to $35.7 million at September 30, 2025, related to new product introductions.
• Interest income decreased by 21.7% in Q3 2025 and 23.7% for the nine months, primarily due to lower interest rates on investment balances.
• General and administrative expenses increased significantly by 23.9% in Q3 2025 and 24.8% for the nine months, driven by personnel costs, stock-based compensation, legal, and consulting fees.

Risks

• DOJ Civil Investigative Demand: Received a CID in October 2024 related to an investigation under the federal Anti-Kickback Statute and Civil False Claims Act concerning meals and consulting payments to healthcare professionals, with a potential material adverse effect on business, results of operations, or financial condition.
• Supply Chain Disruptions: Reliance on single or limited source suppliers for materials (e.g., titanium, impacted by geopolitical events) and third-party sterilizers, which could lead to reductions or interruptions in supply, increased costs, or inability to meet demand.
• Stock Price Volatility: The trading price of common stock may fluctuate substantially due to macroeconomic factors (inflation, interest rates, economic downturn), clinical trial results, regulatory actions, competition, litigation, and changes in key personnel.
• Inadequate Funding for FDA and Government Agencies: Government shutdowns (e.g., October 1, 2025 shutdown mentioned) or workforce reductions could delay product review/approval and impact the ability to access public markets for capital.
• Credit Access Limitations: The ability to access credit on favorable terms for funding operations and capital projects may be limited due to changes in credit markets, and the company will need to renew or refinance its Third Amendment Term Loan by its September 1, 2029 maturity date.
• Uncertainty in Coverage and Reimbursement Environment: Changes to CPT code definitions (e.g., CPT Code 27279 effective January 1, 2026) could lead to lower-quality evidence procedures being reported under the same code, potentially devaluing the code, prompting reevaluations by third-party payers, and decreasing demand for products. Physician confusion over proper coding could also adversely affect demand.
• Need for Additional Capital: Despite current liquidity, the company may need to raise additional capital sooner than expected due to potential decreases in sales, changes in operating expenses or business strategy, regulatory developments, R&D spending, or the capital required for new product offerings (inventory and instrument trays).

Future Outlook

The company expects to incur additional losses in the future but believes existing cash and marketable securities will fund operating expenses and capital expenditure requirements for the next 12 months from the filing date. However, it acknowledges potential challenges and uncertainties, including the need for additional capital if sales decrease, business changes affect expenses, or new product offerings require significant inventory and instrument tray purchases. The company will continue to invest in research and development initiatives to bring new solutions to market and expand its platform of sacropelvic solutions.

Management Comments

• We are a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy.
• Leveraging our knowledge of pelvic anatomy and biomechanics, we have pioneered proprietary minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures.
• As we expand our portfolio, the experience, caliber, and strong clinician relationships of our sales force, including our network of third-party sales agents, will be crucial to drive adoption of our future products and procedures.
• Robust clinical evidence is central to drive adoption and favorable reimbursement, and we remain focused on continuing to set the industry standard in delivering evidence-based care through best-in-class clinical trials that demonstrate the efficacy, safety, and economic benefit of our solutions.
• Based upon our current operating plan, we believe that our existing cash and marketable securities will enable us to fund our operating expenses and capital expenditure requirements over the next 12 months from the filing of this Form 10-Q.

Industry Context

SI-BONE operates in the competitive medical device industry, specifically focusing on minimally invasive surgical solutions for sacropelvic disorders. The company's strategy of expanding its product portfolio (e.g., iFuse INTRA, iFuse TORQ TNT) and investing in clinical evidence (SILVIA, SAFFRON, STACI studies) aligns with broader industry trends emphasizing innovation, evidence-based medicine, and market expansion into areas like ambulatory surgery centers (ASCs). The ongoing regulatory scrutiny, such as the DOJ investigation, highlights the compliance challenges faced by medical device companies, particularly concerning interactions with healthcare professionals. The evolving reimbursement landscape, including changes to CPT codes, is a critical factor influencing demand and market access for new and existing procedures in the medical device sector.

Comparison to Industry Standards

• The company's gross margin of 79.8% is strong for a medical device company, indicating efficient cost of goods sold relative to revenue, which is generally competitive within the high-value implant sector.
• The increase in revenue per territory sales manager from $1.8 million to $2.1 million (trailing 12 months) suggests improved sales force productivity, which is a key performance indicator for medical device companies aiming for efficient market penetration and growth.
• The company's continued investment in R&D, representing 9% of revenue, is a healthy commitment to innovation, comparable to other growth-oriented medical device firms that rely on new product development to maintain competitive advantage.
• The company's focus on clinical trials (SILVIA, SAFFRON, STACI) to demonstrate efficacy and safety is standard practice for medical device companies seeking to establish market leadership and secure favorable reimbursement, especially in evolving procedural areas.
• The company's reliance on third-party manufacturers and sterilizers is common in the medical device industry, but also exposes it to supply chain risks, a challenge many companies in the sector face, particularly with global geopolitical events impacting raw material sourcing like titanium.

Management Changes

Corporate Governance

Legal Proceedings

• Received a Civil Investigative Demand (CID) from the U.S. Department of Justice, Civil Division, in October 2024, in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act. The CID requests information and documents primarily relating to meals and consulting service payments provided to health care professionals. The company is cooperating but is unable to estimate the likely duration, outcome, or financial impact, noting a potential material adverse effect on its business, results of operations, or financial condition.

Related Party Transactions

• A consulting agreement was entered into with Daniel Wolf and Convergence Bio Advisors LLC (wholly owned by Wolf) on November 6, 2025, following Wolf's resignation from the Board. This agreement includes accelerated vesting of 8,675 restricted stock units granted to Wolf on June 5, 2025, and compensation at an hourly rate for services related to marketing, strategy, and business development.

Stakeholder Impact

• Shareholders: Positive financial performance (revenue growth, reduced losses) could be favorable, but ongoing net losses, increasing accumulated deficit, and potential need for future capital raises could dilute equity or impact share value. The DOJ investigation and CPT code changes introduce significant uncertainty and risk.
• Employees: Continued investment in sales force expansion and R&D suggests growth opportunities. Focus on enhancing employee experience and engagement aims to improve retention and satisfaction.
• Customers (Physicians/Hospitals/ASCs): Expanded product portfolio and clinical evidence (SILVIA, SAFFRON, STACI studies) aim to provide more comprehensive solutions and support adoption. Uncertainty in reimbursement policies could affect physician adoption of procedures.
• Suppliers: Increased inventory build-up and efforts to reduce lead times and costs indicate ongoing collaboration and potential for increased volume, but also pressure on efficiency.
• Creditors (First-Citizens Bank & Trust Company): The company is in compliance with debt covenants, and the Fourth Amendment to the loan agreement adjusts financial covenants, providing some flexibility but also strict conditions for future performance.

Next Steps

• Execute an amendment to the Loan and Security Agreement to document Net Revenue covenant levels for the fiscal year ending December 31, 2026, by the earlier of September 30, 2026, or when unrestricted cash falls below a specified threshold.
• Execute an amendment to the Loan and Security Agreement to reset Net Revenue covenant levels for the fiscal year ending December 31, 2027, and any fiscal year thereafter, by February 28th of each year, beginning February 28, 2027.
• Continue to cooperate with the U.S. Department of Justice's Civil Investigative Demand regarding the Anti-Kickback Statute and Civil False Claims Act investigation.
• Continue to invest in research and development initiatives to bring new and differentiated solutions to the market.
• Monitor and evaluate the impact of new accounting pronouncements (ASU 2023-09, ASU 2024-03, ASU 2025-05, ASU 2025-06) on financial statements and disclosures.
• Continue efforts to optimize business processes, increase sales force productivity, and improve asset utilization, including working with suppliers to reduce lead times and costs.
• Manage the upcoming maturity of the Third Amendment Term Loan on September 1, 2029, and assess potential refinancing needs.
• Monitor the evolving coverage and reimbursement environment, particularly changes to CPT Code 27279 effective January 1, 2026, and their potential impact on product demand.

Key Dates

Recommendation

SI-BONE demonstrates strong operational momentum with significant revenue growth and a notable reduction in net losses, indicating improving business fundamentals. The expansion of its product portfolio, positive clinical trial results, and increased sales force productivity are encouraging. However, the company continues to operate at a net loss, has an increasing accumulated deficit, and faces substantial risks, including a material DOJ investigation, potential supply chain disruptions, and significant uncertainty regarding future reimbursement policies for its procedures. While the operational improvements are positive, these unresolved risks and the continued need for capital suggest a 'hold' recommendation, advising investors to monitor the resolution of legal and regulatory uncertainties and the path to sustained profitability before making further investment decisions.

Keywords

Medical Devices, Sacroiliac Joint Fusion, Minimally Invasive Surgery, SEC Filing, 10-Q, Financial Results, Revenue Growth, Net Loss, Operating Cash Flow, Loan Agreement, Financial Covenants, Clinical Trials, Supply Chain, Regulatory Risk, Reimbursement, Corporate Governance, SI-BONE, Orthopedics, Spinal Surgery